I have not seen any private placements or convertibles done at deep discounts lately. I believe the rationale for the increase has to do with the drug trial.
I hope the patent is issued in Q1 and that could open up a world of possibilities because the nausea chemo market is a $7 billion dollar annual spend for drugs that are somewhat effective with side effects.
I suspect that the original patent could have been approved already, but that was for gum delivery only. As I understand it, the patent application was changed to include other orals. Obviously, chewing gum delivery also has an additional process patent.
After the $7.2 Billion dollar buyout of the only FDA approved drug this year you can bet Big Pharma is exploring ways to monetize CBD, and not just CBD but mushrooms as well.
Nestles had no CBD products when Taurigum was launched. Nestles approved its largest Hagen das distributer to distribute the gum 2 years ago. Unfortunately, right after that approval, the Governor of New York banned CBD sales. That ban has now been lifted.
Nestles, as well as other food companies, sell CBD products. Garden Of Life is actually in the safety trial Cohort with Tauriga.
I am sure you are aware of that as I have posted that several times months ago along with their PowerPoint.
This is currently a $12 million dollar market cap. Not only does that seem stupidly low based on their retail products, but the potential of a positive drug trial is huge. Granted, drug trails are risky and not guaranteed by any means, but this trial is not attempting to cure a disease, but it is to mitigate he nausea effects of Chemotherapy treatments.
There is also quite a potential for an over the counter nausea chewing gum.
The stock price has certainly been disappointing over the last 6 months for sure. But with chains like Pilot picking up the gum the retail looks promising. There will be a day when the CVS's Walmart's Amazon's Target's of the world allow CBD sales, and that could also be a huge win.
